Motexafin gadolinium enhances the efficacy of aminolevulinic acid mediated-photodynamic therapy in human glioma spheroids

Journal of Neuro-Oncology

Volumn 91, Issue 2, 2009, Pages 141-149

  Madsen, Steen J ^a   Mathews, Marlon S ^b,c   Angell Petersen, Even ^d   Sun, Chung Ho ^b   Vo, Van ^a   Sanchez, Rogelio ^b   Hirschberg, Henry ^a  

^a UNIVERSITY OF NEVADA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

5 aminolevulinic acid; Glioma; Invasive growth; Motexafin gadolinium; Photodynamic therapy; Spheroid

Indexed keywords

AMINOLEVULINIC ACID; GADOLINIUM TEXAPHYRIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; GLIOMA; GLIOMA CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PHOTODYNAMIC THERAPY; TUMOR SPHEROID;

AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG SYNERGISM; ETHIDIUM; GLIOMA; HUMANS; METALLOPORPHYRINS; NEOPLASM INVASIVENESS; PHOTOCHEMOTHERAPY; SPHEROIDS, CELLULAR; TIME FACTORS;

EID: 57349149646     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9692-4     Document Type: Article

References (62)

1. Stupp R, van den Bent MJ, Hegi ME (2005) Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 5:198-206. doi: 10.1007/s11910-005-0047-7
2. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG (1989) Patterns of failure following treatments for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405-1409
3. Muller PJ, Wilson BC, Lilge LD, Yang V, Hetzel FW, Chen Q et al (2001) Photofrin photodynamic therapy for malignant brain tumors. In: Dougherty TJ (ed) Optical methods for tumor treatment and detection: Mechanisms and techniques in photodynamic therapy. Proceedings SPIE, vol 4248, April 2001, SPIE Publishers, Bellingham, WA, pp 34-41
4. Eljamel MS, Goodman C, Moseley H (2007) ALA and Photofrin® fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: A single centre phase III randomised controlled trial. Lasers Med Sci. doi: 10.1007/s10103-007-0494-2
5. Beck TJ, Kreth FW, Beyer W, Mehrkens JH, Obermeier A, Stepp H et al (2007) Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX. Lasers Surg Med 39(5):386-393. doi: 10.1002/lsm.20507
6. Dougherty TJ (1993) Photodynamic therapy. Photochem Photobiol 58:895-900. doi: 10.1111/j.1751-1097.1993.tb04990.x
7. Lilge L, Wilson BC (1998) Photodynamic therapy of intracranial tissues: a preclinical comparative study of four different photosensitizers. J Clin Laser Med Surg 16:81-92
8. Hebeda KM, Saarnak AE, Olivo M, Sterenborg HJ, Wolbers JG (1998) 5-Aminolevulinic acid induced endogenous porphyrin fluorescence in 9L and C6 brain tumours and in the normal rat brain. Acta Neurochir (Wien) 140:503-513. doi: 10.1007/s007010050132
9. Lilge L, Portnoy M, Wilson BC (2000) Apoptosis induced in vivo by photodynamic therapy in normal brain and intracranial tumor tissue. Br J Cancer 83:1110-1117. doi: 10.1054/bjoc.2000.1426
10. Obwegeser A, Jakober R, Kostron H (1998) Uptake and kinetics of 14C-labelled meta-tetrahydroxylchlorin and 5-aminolevulinic acid in the C6 rat glioma model. Br J Cancer 78:733-738
11. Stummer W, Stocker S, Novotny A, Heimann A, Sauer O, Kempski O et al (1998) In vitro and in vivo porphyrin accumulation by C6 glioma cells after exposure to 5-aminolevulinic acid. J Photochem Photobiol B Biol 45:160-169. doi: 10.1016/S1011-1344(98)00176-6
12. Stummer W, Stocker S, Wagner S, Stepp H, Fritsch C, Goetz C et al (1998) Intraoperative detection of malignant gliomas by 5-aminolevulinic acid induced porphyrin fluorescence. Neurosurgery 42:518-526. doi: 10.1097/ 00006123-199803000-00017
13. Terr L, Weiner LP (1983) An autoradiographic study of 5-aminolevulinic acid uptake by mouse brain. Exp Neurol 79:564-568. doi: 10.1016/ 0014-4886(83)90234-0
14. Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ (2000) Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: A prospective study in 52 consecutive patients. J Neurosurg 93:1003-1013
15. Angell-Petersen E, Hirschberg H, Madsen SJ (2007) Determination of fluence rate and temperature distributions in the rat brain; implications for photodynamic therapy. J Biomed Opt 12(1):014003-1-014003-9
16. Sessler JL, Burrell AK (1992) Expanded porphyrins. Top Curr Chem 161:177-273
17. Magda D, Miller RA (2006) Motexafin gadolinium: A novel redox active drug for cancer therapy. Semin Cancer Biol 16(6):466-476. doi: 10.1016/ j.semcancer.2006.09.002
18. Evens AM (2004) Motexafin gadolinium: A redox-active tumor selective agent for the treatment of cancer. Curr Opin Oncol 16(6):576-580. doi: 10.1097/01.cco.0000142073.29850.98
19. Madsen SJ, Sun C-H, Tromberg BJ, Wallace VP, Hirschberg H (2000) Photodynamic therapy of human glioma spheroids using 5-aminolevulinic acid. Photochem Photobiol 72(1):128-134. doi:10.1562/ 0031-8655(2000)072<0128:PTOHGS>2.0.CO;2
20. Sutherland RM, Carlsson J, Durand RE, Yuhas J (1981) Spheroids in cancer research. Cancer Res 41:2980-2994
21. Drewinko B, Loo TL, Brown B, Gottlieb JA, Freireich EJ (1976) Combination therapy in vitro with adriamycin: Observation of additive, antagonistic, and synergistic effects when used in two-drug combinations on cultured human lymphoma cells. Cancer Biochem Biophys 1:187-195
22. Hirschberg H, Sun C-H, Krasieva T, Madsen SJ (2006) Effects of ALA-mediated photodynamic therapy on the invasiveness of human glioma cells. Lasers Surg Med 38:939-945. doi: 10.1002/lsm.20445
23. Mathews MS, Sun C-H, Madsen SJ, Hirschberg H (2007) Comparing the effects of repetitive and chronic PDT in human glioma spheroids. In: Kollias N, Choi B, Zeng H et al (eds) Photonic therapeutics and diagnostics III. Proceedings SPIE, vol 6424, SPIE Publishers, Bellingham, WA, pp D1-D9
24. Madsen SJ, Sun C-H, Tromberg BJ, Hirschberg H (2003) Repetitive 5-aminolevulinic acid-mediated photodynamic therapy on human glioma spheroids. J Neurooncol 62(3):243-250. doi: 10.1023/A:1023362011705
25. Giese A, Loo MA, Tran N, Haskett D, Coons SW, Berens ME (1996) Dichotomy of astrocytoma migration and proliferation. Int J Cancer 67:275-282. doi:10.1002/(SICI)1097-0215(19960717)67:2<275::AID-IJC20>3.0.CO;2-9
26. Giese A, Loo MA, Rief MD, Tran N, Berens ME (1995) Substrates for astrocytoma invasion. Neurosurgery 37:294-302. doi: 10.1097/ 00006123-199508000-00015
27. Binder DK, Berger MS (2002) Proteases and the biology of glioma invasion. J Neurooncol 56:149-158. doi: 10.1023/A:1014566604005
28. Rao JS (2000) Molecular mechanisms of glioma invasiveness: The role of proteases. Nat Rev Cancer 3(7):489-501. doi: 10.1038/nrc1121
29. Uhm JH, Dooley NP, Villemure JG, Yong VW (1997) Mechanisms of glioma invasion: Role of matrix-metalloproteinases. Can J Neurol Sci 24:3-15
30. Koul D, Parthasarathy R, Shen R, Davies MA, Jasser SA, Chintala SK et al (2001) Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 20:6669-6678. doi: 10.1038/sj.onc.1204799
31. Maidment SL (1997) The cytoskeleton and brain tumour cell migration. Anticancer Res 17:4145-4149
32. Chicoine MR, Silbergeld DL (1995) Assessment of brain tumor cell motility in vivo and in vitro. J Neurosurg 82:615-622
33. Muller PJ, Wilson BC (1986) An update on the penetration depth of 630 nm light in normal and malignant human brain tissue in vivo. Phys Med Biol 31:1295-1297. doi: 10.1088/0031-9155/31/11/012
34. Wilson BC, Jeeves WP, Lowe DM (1985) In vivo and post mortem measurements of the attenuation spectra of light in mammalian tissues. Photochem Photobiol 42:153-162. doi: 10.1111/j.1751-1097.1985.tb01554.x
35. Doiron DR, Svaasand LO, Profio AE (1983) Light dosimetry in tissue applications to photoradiation therapy. In: Kessel D, Dougherty TJ (eds) Porphyrin photosensitization. Plenum Press, New York, pp 63-75
36. Powers SK, Brown JT (1986) Light dosimetry in brain tissue: An in vivo model applicable to photodynamic therapy. Lasers Surg Med 6:318-322. doi: 10.1002/lsm.1900060305
37. Chen Q, Chopp M, Madigan L, Dereski MO, Hetzel FW (1996) Damage threshold of normal rat brain in photodynamic therapy. Photochem Photobiol 64:163-167. doi: 10.1111/j.1751-1097.1996.tb02437.x
38. Madsen SJ, Sun C-H, Tromberg BJ, Hirschberg H (2001) Development of a novel indwelling balloon applicator for optimizing light delivery in photodynamic therapy. Lasers Surg Med 29:406-412. doi: 10.1002/lsm.10005
39. Bisland SK, Lilge L, Lin A, Rusnow R, Wilson BC (2004) Metronomic photodynamic therapy as a new paradigm for photodynamic therapy: rationale and preclinical evaluation of technical feasibility for treating malignant brain tumors. Photochem Photobiol 80:22-30. doi: 10.1562/2004-03-05-RA-100.1
40. Sessler JL, Miller RA (2000) Texaphyrins: New drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol 59:733-739. doi: 10.1016/S0006-2952(99)00314-7
41. Khuntia D, Mehta M (2004) Motexafin gadolinium: A clinical review of a novel radioenhancer for brain tumors. Expert Rev Anticancer Ther 4:981-989. doi: 10.1586/14737140.4.6.981
42. Carde P, Timmerman R, Mehta MP, Koprowski CD, Ford J, Tishler RB et al (2001) Multicenter phase IB/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 19:2074-2083
43. Hirschberg H, Wu GN, Madsen SJ (2007) Evaluation of motexafin gadolinium (MGd) as a contrast agent for intraoperative MRI. Minim Invasive Neurosurg 50:1-6. doi: 10.1055/s-2007-993158
44. Donnelly ET, Liu YF, Fatunmbi YO, Lee I, Magda D, Rockwell S (2004) Effects of texaphyrins on the oxygenation of EMT6 mouse mammary tumors. Int J Radiat Oncol Biol Phys 58(5):1570-1576. doi: 10.1016/ j.ijrobp.2003.12.017
45. Wu GN, Ford JM, Alger JR (2006) MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain. J Neurooncol 77:95-103. doi: 10.1007/ s11060-005-9101-1
46. Hirschberg H, Sørensen DR, Angell-Petersen E, Peng Q, Tromberg B, Sun CH et al (2006) Repetitive photodynamic therapy of malignant brain tumors. J Environ Pathol Toxicol Oncol 25(1-2):261-280
47. Viala J, Vanel D, Meingan P, Lartigau E, Carde P, Renschler MF (1999) Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: Preliminary results in brain metastases. Radiology 212:755-759
48. Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA et al (2002) Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: Centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 20:3445-3453. doi: 10.1200/JCO.2002.07.500
49. Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W et al (2003) Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21(13):2529-2536. doi: 10.1200/JCO.2003.12.122
50. Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T et al (2004) Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 22(1):157-165. doi: 10.1200/JCO.2004.05.128
51. Rosenthal DI, Nurenberg P, Becerra CR, Frenkel EP, Carbone DP, Lum BL et al (1999) A phase I single dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 5:739-745
52. Miller RA, Woodburn K, Fan Q, Renschler MF, Sessler JL, Koutcher JA (1999) In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer. Int J Radiat Oncol Biol Phys 45(4):981-989. doi: 10.1016/S0360-3016(99)00274-6
53. De Stasio G, Rajesh D, Ford JM, Daniels MJ, Erhardt RJ, Frazer BH et al (2006) Motexafin-gadolinium taken up in vitro by at least 90% of glioblastoma cell nuclei. Clin Cancer Res 12(1):206-213. doi: 10.1158/ 1078-0432.CCR-05-0743
54. Woodburn KW (2001) Intracellular localization of the radiation enhancer motexafin gadolinium using interferometric Fourier fluorescence microscopy. J Pharmacol Exp Ther 297:888-894
55. Hirschberg H, Mathews MS, Angell-Petersen E, Spetalen S, Madsen SJ (2007) Increased brain edema following 5-aminolevulinic acid administration mediated photodynamic therapy in normal and tumor-bearing rats. In: Kollias N, Choi B, Zeng H et al (eds) Photonic therapeutics and diagnostics III. Proceedings SPIE, vol 6424, SPIE Publishers, Bellingham, WA, pp B1-B8
56. Hirschberg H, Zhang M, Chighvinadze D, Peng Q, Madsen SJ (2008) Targeted opening of the blood brain barrier by ALA mediated PDT. In: Kollias N, Choi B, Zeng H et al (eds) Photonic therapeutics and diagnostics IV. Proceedings SPIE, vol 6842, SPIE Publishers, Bellingham, WA, pp O1-O11
57. Madsen SJ, Angell-Petersen E, Spitalen S, Carper SW, Ziegler S, Hirschberg H (2006) Photodynamic therapy of newly implanted glioma cells in the rat brain. Lasers Surg Med 38:540-548. doi: 10.1002/lsm.20274
58. Madsen SJ, Kharkhuu K, Hirschberg H (2007) Utility of the F98 rat glioma model for photodynamic therapy. J Environ Pathol Toxicol Oncol 26(2):149-155
59. Madsen SJ, Sun C-H, Tromberg BJ, Yeh AT, Sanchez R, Hirschberg H (2002) Effects of combined photodynamic therapy and ionizing radiation on human glioma spheroids. Photochem Photobiol 76:411-416. doi:10.1562/ 0031-8655(2002)076<0411:EOCPTA>2.0.CO;2
60. Hirschberg H, Sun C-H, Yeh AT, Tromberg BJ, Madsen SJ (2004) Enhanced effects of concurrent 5-aminolevulinic acid-mediated photodynamic therapy by hyperthermia on human glioma spheroids. J Neurooncol 70:289-299. doi: 10.1007/s11060-004-9161-7
61. Iinuma S, Farshi SS, Ortel B, Hasan T (1994) A mechanistic study of cellular photodestruction with 5-aminolevulinic acid-induced porphyrin. Br J Cancer 70:21-28
62. Verma A, Facchina SL, Hirsch DJ, Song S-Y, Dillahey LF, Williams JR et al (1998) Photodynamic tumor therapy: Mitochondrial benzodiazepine receptors as a therapeutic target. Mol Med 4:40-48